Concerns following event on HAVEN1 trial.
Company reports better than expected full year figures.
Patients could be denied treatments, says BIA
Settlement relates to investigation into Dermagraft sales.
Roche hopes to take on Novo Nordisk and Shire.
Potential liver blockbuster gets EU licence.
New facility in Cambridge, Massachusetts.
Onivyde not eligible for Cancer Drugs Fund, says NICE.